Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer ...
A major new review suggests intermittent fasting may not be the weight-loss shortcut you think it is.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results